Agustin Lage

Agustin Lage

Auto-generated profile, based on publicly available information

Agustin Lage

Clinical Research Division, Center of Molecular Immunology, Calle 216 esq 15. Atabey, 11600, Havana, Cuba

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
ALAgustin Lage
Agustin Lage
TCTania Crombet
Tania Crombet
Despite the recent trend toward a slight decrease in age-adjusted cancer mortality in some countries, crude mortality rates will continue to increase, driven by the demographic shift towards an aged population. Small molecules (small molecules and biologics) are not only a new therapeutic acquisition, but the tools of a more fundamental transition: the transformation of cancer from a rapidly fatal disease into a chronic condition. Antibodies and cancer vaccines can be used for a long time, even beyond progressive disease, and in aged patients, usually unfit for more aggressive conventional treatments. However, this transition to chronicity will require novel developmental guidelines adequate to this kind of drugs, for which optimal dose is not usually the maximal tolerated dose, pharmacokinetics does not define treatment schedule, and tumor shrinkage is not a good correlate of survival. The ongoing cancer immunotherapy program (including several monoclonal antibodies and therapeutic vaccines) at the Centre of Molecular Immunology can illustrate the issues to be addressed, both biological and social, along the path to transform advanced cancer into a chronic non-communicable disease compatible with years of quality life.

1 January 2011 in Journal of Immune Based Therapies and Vaccines
Verified
Journal Article
Open access
PDF file
PRPedro C Rodriguez
Pedro C Rodriguez
ENElia Neninger
Elia Neninger
BGBeatriz García
Beatriz García
XPXitlally Popa
Xitlally Popa
CVCarmen Viada
Carmen Viada
TCTania Crombet
Tania Crombet
The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical trials, patients started vaccination 1 month after finishing first line chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high dose) was very safe. The most frequent adverse events were grade 1 or 2 injection site reactions, fever, headache and vomiting. Patients had a trend toward higher antibody response. The percent of very good responders significantly augmented and there was a faster decrease of circulating EGF. All vaccinated patients and those classified as good responders immunized with high dose at 4 sites, had a large tendency to improved survival.

30 April 2013 in Immunity & Ageing
Verified
Journal Article
Open access
PDF file
BVBeatriz García Verdecia
Beatriz García Verdecia
DSDanay Saavedra
Danay Saavedra
PLPatricia Lorenzo-Luaces
Patricia Lorenzo-Luaces
TATeresita de Jesús Badía Alvarez
Teresita de Jesús Badía Alvarez
IRIdrissa Leonard Rupalé
Idrissa Leonard Rupalé
ADAgustín Lage Dávila
Agustín Lage Dávila
The progressive decline in the immune function during ageing is termed immunosenescence. Previous studies have reported differences between males and females in the distribution and cell responses of lymphocyte subsets. Most studies of immunosenescence have been done in populations of industrialized countries living in a rather cold environment, and facing lower antigenic challenges such as Cytomegalovirus (CMV). The aim of this study was to determine the effect of ageing on lymphocytes in a population with a high prevalence of CMV infection in all ages, and to compare gender differences related to the immunosenescence markers. Different populations of peripheral blood leukocytes from healthy young and old IgG-CMV seropositive individuals were examined using flow cytometry. With age, the number and frequency of B cells and T cells significantly decreased, while highly differentiated T cells increased. Such changes were different in males and females. The age-associated decline of less differentiated lymphocyte subsets (CD19, CD4 and CD8 cells) and the increase of highly differentiated T cells were more prominent in females. In males, there were no significant changes in CD19, CD4 and CD8 subsets but there was a significant increase in the proportion of highly differentiated T cells. Shifts in lymphocyte subsets distribution were influenced by age and gender in an IgG-CMV seropositive population. These results suggest different patterns of immunosenescence in respect to gender differences. These patterns could have implications in the design of immunotherapy in the elderly.

1 January 2010
Verified
Journal Article
Closed access
PRPedro C Rodríguez
Pedro C Rodríguez
GRGryssell Rodríguez
Gryssell Rodríguez
GGGisela González
Gisela González
ALAgustín Lage
Agustín Lage

1 January 2018 in Seminars in Oncology
Verified
Journal Article
Closed access
PDF file
LSLizet Sanchez
Lizet Sanchez
LMLeacky Muchene
Leacky Muchene
PLPatricia Lorenzo-Luaces
Patricia Lorenzo-Luaces
CVCarmen Viada
Carmen Viada
PRPedro C. Rodriguez
Pedro C. Rodriguez
ALAgustin Lage
Agustin Lage

1 February 2008 in Nature Immunology
Verified
Journal Article
Closed access
ALAgustin Lage
Agustin Lage